EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31

Wenqin Sun, Iris L K Wong, Helen Ka-Wai Law iD, Xiaochun Su, Terry C F Chan, Gege Sun, Xinqing Yang, Xingkai Wang, Tak Hang Chan, Shengbiao Wan, Larry M C Chow

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wenqin Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University,…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Catechin, Leukemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSFC/RGC Joint Research Scheme, the Project of Strategic Importance of the Hong Kong Polytechnic University and the State Key Laboratory of the Chemical Biology and Drug Discovery.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The modulation of P-glycoprotein (P-gp, ABCB1) can reverse multidrug resistance (MDR) and potentiate the efficacy of anticancer drugs. Tea polyphenols, such as epigallocatechin gallate (EGCG), have low P-gp-modulating activity, with an EC50 over 10 μM. In this study, we optimized a series of tea polyphenol derivatives and demonstrated that epicatechin EC31 was a potent and nontoxic P-gp inhibitor. Its EC50 for reversing paclitaxel, doxorubicin, and vincristine resistance in three P-gp-overexpressing cell lines ranged from 37 to 249 nM. Mechanistic studies revealed that EC31 restored intracellular drug accumulation by inhibiting P-gp-mediated drug efflux. It did not downregulate the plasma membrane P-gp level nor inhibit P-gp ATPase. It was not a transport substrate of P-gp. A pharmacokinetic study revealed that the intraperitoneal administration of 30 mg/kg of EC31 could achieve a plasma concentration above its in vitro EC50 (94 nM) for more than 18 h. It did not affect the pharmacokinetic profile of coadministered paclitaxel. In the xenograft model of the P-gp-overexpressing LCC6MDR cell line, EC31 reversed P-gp-mediated paclitaxel resistance and inhibited tumor growth by 27.4 to 36.1% (p < 0.001). Moreover, it also increased the intratumor paclitaxel level in the LCC6MDR xenograft by 6 fold (p < 0.001). In both murine leukemia P388ADR and human leukemia K562/P-gp mice models, the cotreatment of EC31 and doxorubicin significantly prolonged the survival of the mice (p < 0.001 and p < 0.01) as compared to the doxorubicin alone group, respectively. Our results suggested that EC31 was a promising candidate for further investigation on combination therapy for treating P-gp-overexpressing cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsCatechinLeukemiaAnimalsFemaleHumansMiceATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorDoxorubicinDrug Resistance, NeoplasmHeterograftsPaclitaxelPolyphenolsTea

Stichwörter der Autor:innen

ECMDRP-glycoproteinP-gpepicatechinmodulatormultidrug resistance

Substanzen

Antineoplastic AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1CatechinDoxorubicinPaclitaxelPolyphenolsTea

Autor:innen und Institutionen

  • State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong SAR, China.
  • Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hong Kong SAR, China.
  • Laboratory for Marine Drugs and Bioproducts of Qingdao, National Laboratory for Marine Science and Technology, Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of…
  • Department of Chemistry, McGill University, Montreal, QC H3A 2K6, Canada.

ORCID-Profile: Helen Ka-Wai Law

Förderung

  • NSFC/RGC Joint Research Scheme
  • the Project of Strategic Importance of the Hong Kong Polytechnic University and the State Key Laboratory of the Chemical Biology and Drug Discovery

Zitieren

APA

Sun, W., Wong, I. L. K., Law, H. K., Su, X., Chan, T. C. F., Sun, G., Yang, X., Wang, X., Chan, T. H., Wan, S., & Chow, L. M. C. (2023). In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054377

Vancouver

Sun W, Wong ILK, Law HK, Su X, Chan TCF, Sun G, et al. In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054377

BibTeX
@article{Sun2023,
  author = {Sun, Wenqin and Wong, Iris L K and Law, Helen Ka-Wai and Su, Xiaochun and Chan, Terry C F and Sun, Gege and Yang, Xinqing and Wang, Xingkai and Chan, Tak Hang and Wan, Shengbiao and Chow, Larry M C},
  title = {In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054377}
}
Kostenlos starten →